During the past decade, Sarah Cannon-Minnie Pearl Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon-Minnie Pearl Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 1 trials, followed by "Case Comprehensive Cancer Center" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Genzyme, a Sanofi Company" with 1 trials sponsored and "Ligand Pharmaceuticals" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon-Minnie Pearl Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator and "Smith Kline Beecham" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon-Minnie Pearl Cancer Center" are "Pancreatic Cancer" (3 trials), "Breast Cancer" (2 trials), "Lung Cancer" (2 trials), "Colorectal Cancer" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "Sarah Cannon-Minnie Pearl Cancer Center" in a lesser frequency.

Most popular intervention types in "Sarah Cannon-Minnie Pearl Cancer Center" are "Drug" (8 trials), "Radiation" (2 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "gemcitabine hydrochloride" (3 trials), "ILX-295501" (1 trials), "bexarotene" (1 trials), "chemotherapy" (1 trials) and "erlotinib hydrochloride" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon-Minnie Pearl Cancer Center" are 7 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Sarah Cannon-Minnie Pearl Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Sarah Cannon-Minnie Pearl Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon-Minnie Pearl Cancer Center, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".